GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cleo Diagnostics Ltd (ASX:COV) » Definitions » Net Current Asset Value

Cleo Diagnostics (ASX:COV) Net Current Asset Value : A$0.08 (As of Dec. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cleo Diagnostics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Cleo Diagnostics's net current asset value per share for the quarter that ended in Dec. 2023 was A$0.08.

The historical rank and industry rank for Cleo Diagnostics's Net Current Asset Value or its related term are showing as below:

ASX:COV' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 2.06   Med: 2.25   Max: 2.25
Current: 2.19

During the past 1 years, the highest Price-to-Net-Current-Asset-Value Ratio of Cleo Diagnostics was 2.25. The lowest was 2.06. And the median was 2.25.

ASX:COV's Price-to-Net-Current-Asset-Value is ranked better than
77.36% of 583 companies
in the Medical Devices & Instruments industry
Industry Median: 4.98 vs ASX:COV: 2.19

Cleo Diagnostics Net Current Asset Value Historical Data

The historical data trend for Cleo Diagnostics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cleo Diagnostics Net Current Asset Value Chart

Cleo Diagnostics Annual Data
Trend Jun23
Net Current Asset Value
-0.03

Cleo Diagnostics Semi-Annual Data
Dec22 Jun23 Dec23
Net Current Asset Value -0.01 -0.03 0.08

Competitive Comparison of Cleo Diagnostics's Net Current Asset Value

For the Medical Devices subindustry, Cleo Diagnostics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cleo Diagnostics's Price-to-Net-Current-Asset-Value Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cleo Diagnostics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Cleo Diagnostics's Price-to-Net-Current-Asset-Value falls into.



Cleo Diagnostics Net Current Asset Value Calculation

Cleo Diagnostics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2023 is calculated as

Net Current Asset Value Per Share(A: Jun. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(0.58-2.02-0-0)/45
=-0.03

Cleo Diagnostics's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

Net Current Asset Value Per Share(Q: Dec. 2023 )
=(Total Current Assets-Total Liabilities-Minority Interest-Preferred Stock)/Shares Outstanding (EOP)
=(10.27-0.199-0-0)/128.5
=0.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cleo Diagnostics  (ASX:COV) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham’s strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.


Cleo Diagnostics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Cleo Diagnostics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Cleo Diagnostics (ASX:COV) Business Description

Traded in Other Exchanges
N/A
Address
480 Collins Street, Level 2, Melbourne, VIC, AUS, 3000
Cleo Diagnostics Ltd is focused on the development of non-invasive blood-based IVD tests to detect the presence, and recurrence, of ovarian cancer. The Company's first product to market is intended to be the Triage Test which has to date produced strong results to accurately differentiate patients with malignant ovarian cancer from those with benign gynaecological conditions. The Company aims to improve the diagnostic process and procedures for detecting ovarian cancer and, in this regard, improve quality-of-life outcomes for patients who have been diagnosed with ovarian cancer.

Cleo Diagnostics (ASX:COV) Headlines

No Headlines